SharpyGLP-1 Long Term Side Effects: What Years of Data Show
The longest GLP-1 studies, about 3 years on average for weight-loss doses of semaglutide and tirzepatide, show the main long term side effects are gallbladder problems, rare pancreatitis, loss of some muscle along with fat, and weight regain after stopping. Thyroid cancer is a warning based on rodent studies, and large human studies have not shown a clear rise. Long term safety past 5 to 10 years for weight loss is still being studied. Talk to your prescriber about your own risks, and protect your muscle with Sharpy, which gives you one protein target, one 20-minute workout and one Shape Score a day.
Are there long term side effects of GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound? Yes, a few are known: gallbladder problems, rare pancreatitis, loss of some muscle along with fat, and weight regain when you stop. The thyroid cancer warning comes from rodent studies, and big human studies have not shown a clear rise so far. What nobody can tell you yet is what happens after 10 or more years at weight-loss doses, because those drugs have not been on the market that long.
This guide sorts what is proven, what is rare, and what is still unknown, using the FDA label (Wegovy, revised June 2026, with Zepbound and Mounjaro carrying similar warnings) and the longest trials.
How long have GLP-1 drugs been studied?
"Long term" means different things for different drugs. Here is how much data exists:
| Drug or trial | What was studied | Longest follow-up |
|---|---|---|
| Exenatide (Byetta) | Type 2 diabetes | On sale since 2005, about 20 years of use |
| Liraglutide (Victoza, Saxenda) | Diabetes, then weight loss | On sale since 2010 |
| SELECT (semaglutide 2.4 mg) | 17,604 adults with heart disease and overweight | Average follow-up 3.3 years |
| STEP 5 (semaglutide 2.4 mg) | Adults with obesity | 2 years |
| SURMOUNT-1 (tirzepatide) | Adults with obesity and prediabetes | 3 years (176 weeks) |
So for diabetes, doctors have two decades of experience with the drug class. For the high weight-loss doses most people search about, the best data stops at about 3 to 4 years.
GLP-1 long term side effects in the label
The FDA label lists these warnings for Wegovy. Zepbound and Mounjaro carry a similar list.
| Warning | What it means | How common |
|---|---|---|
| Thyroid C-cell tumors (boxed warning) | Seen in rats and mice; unknown in humans | Not shown in people so far |
| Gallbladder disease | Gallstones and inflamed gallbladder | Gallstones 1.6% vs 0.7% on placebo |
| Acute pancreatitis | Inflamed pancreas, severe belly pain | Rare |
| Kidney injury | From dehydration after vomiting or diarrhea | Rare, postmarketing reports |
| Faster heart rate | Resting heart rate goes up a few beats | Common, usually mild |
| Diabetic eye changes | Only in people with type 2 diabetes and retinopathy | Mostly with fast blood sugar drops |
| Severe stomach side effects | Severe nausea, vomiting or diarrhea; not advised with severe gastroparesis | Added to the label in October 2025 |
| Aspiration during anesthesia | Food left in the stomach during sedation | Rare; tell your surgeon you take it |
In the main Wegovy weight trials, 6.8% of people stopped the drug because of side effects, compared with 3.2% on placebo. Nausea, vomiting and diarrhea were the top reasons.
Gallbladder problems: the most common lasting risk
Fast weight loss of any kind, even from dieting or surgery, raises the chance of gallstones. GLP-1 drugs add to that. In the Wegovy trials, inflamed gallbladder (cholecystitis) showed up in 0.6% of people versus 0.2% on placebo. Pain in the upper right belly, fever or yellow skin needs a doctor. Our guide to GLP-1 and your gallbladder covers signs and ways to lower the risk.
Pancreatitis and the pancreas
Acute pancreatitis is rare but serious. The label says to stop the drug and get checked if you have severe belly pain that may spread to your back. Whether GLP-1s raise pancreatic cancer risk has been studied for years, and large studies have not confirmed a link. More detail is in GLP-1 and pancreatitis.
GLP-1 long term side effects and cancer
This is the worry people search most. Here is what the evidence says:
- Thyroid: Rodents got C-cell tumors. A 2024 BMJ study of about 145,000 GLP-1 users in Denmark, Norway and Sweden followed for about 4 years on average found no clear rise in thyroid cancer compared with users of another diabetes drug (DPP-4 inhibitors). The label still says not to use these drugs if you or a family member had medullary thyroid cancer or MEN 2. See our thyroid warning guide.
- Obesity-related cancers: A 2024 JAMA Network Open study of people with type 2 diabetes found GLP-1 users had lower rates of 10 of 13 obesity-related cancers than insulin users. New observational studies like this keep appearing, including one reported this week. They show links, not proof. For every study, cancer by cancer, see our GLP-1 cancer risk guide.
Muscle loss and bone density
Weight loss takes some lean mass with it. In the STEP 1 body scan substudy, roughly 40% of the weight people lost on semaglutide was lean mass. Lean mass is not only muscle; it also includes water and organs. Still, losing muscle year after year can make you weaker and slow your metabolism, and bone density can drop with fast weight loss too (see GLP-1 and bone density).
This is the long term side effect you can do the most about. Two habits help:
- Protein at every meal, often around 1.2 to 1.6 grams per kilogram of goal body weight a day. Ask your care team what fits you. Our protein target guide shows how to hit it with a small appetite.
- Strength training 2 to 3 times a week.
Sharpy is built around this. It sets one daily protein target, gives you one 20-minute workout and tracks a Shape Score, so you can see if you are losing fat and keeping muscle.
Hair loss, eyes and other side effects people ask about
- Hair loss: 3.3% of people on Wegovy 2.4 mg reported it versus 1% on placebo, and the label ties it to weight loss. It is usually the temporary shedding that follows any fast weight loss.
- Vision (NAION): Europe lists this rare optic nerve problem as a very rare semaglutide side effect, up to 1 in 10,000 people. The June 2026 US Wegovy label does not list it. Read Ozempic vision loss and NAION.
- Mood: In January 2024 the FDA said its review found no evidence that GLP-1 drugs cause suicidal thoughts, and the European Medicines Agency reached the same conclusion. The Wegovy label removed its suicidal behavior warning in February 2026. Tell your doctor about any mood changes anyway.
What happens long term after you stop
The most predictable long term effect is what happens when the drug stops. In the STEP 1 extension, people regained about two thirds of the weight they lost within one year off semaglutide. Blood pressure and blood sugar gains faded too. This is why the labels describe these as long term medicines. If you and your prescriber plan to stop, our guide on how to stop a GLP-1 without rebound covers what helps. Never stop or change your dose without talking to your prescriber.
The long term benefits, for balance
The same long trials also showed benefits. In SELECT, semaglutide 2.4 mg lowered heart attacks, strokes and heart deaths by 20% compared with placebo in people with heart disease. In SURMOUNT-1, 1.3% of people with prediabetes on tirzepatide developed type 2 diabetes over 3 years, versus 13.3% on placebo. The trade-off showed up too: in SELECT, 16.6% of people stopped semaglutide because of side effects, versus 8.2% on placebo.
What is still unknown
- Safety after 10 or more years at weight-loss doses.
- Long term effects in teens who start young.
- Effects of stopping and restarting many times.
- How much lost muscle comes back after stopping.
The bottom line
The known GLP-1 long term side effects are real but mostly uncommon: gallstones, rare pancreatitis, some lean mass loss and weight regain after stopping. The thyroid warning comes from animals, and human data so far are reassuring. The biggest gap is time: nobody has 10-year data for weight-loss doses yet. Keep regular check-ups, report new symptoms, and protect your muscle while you lose fat. Sharpy makes that one protein target and one 20-minute workout a day.
Sources
- Wegovy prescribing information, revised 06/2026, DailyMed
- Lincoff et al., Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT), NEJM 2023
- Garvey et al., Two-year effects of semaglutide in adults with overweight or obesity (STEP 5), Nature Medicine 2022
- Wilding et al., Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension), Diabetes Obes Metab 2022
- Wilding et al., Once-weekly semaglutide in adults with overweight or obesity (STEP 1), NEJM 2021
- Jastreboff et al., Tirzepatide for obesity treatment and diabetes prevention (SURMOUNT-1, 3 years), NEJM 2025
- Pasternak et al., Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer, BMJ 2024
- Wang et al., GLP-1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes, JAMA Network Open 2024
- FDA: Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking GLP-1 receptor agonists, January 2024
- EMA: PRAC concludes eye condition NAION is a very rare side effect of semaglutide, June 2025
Questions people ask
What are the long term side effects of GLP-1 medications?
From the FDA labels and the longest trials, the main long term concerns are gallbladder disease (gallstones), acute pancreatitis (rare), loss of some lean mass along with fat, hair loss during fast weight loss, faster heart rate, and weight regain after stopping. The labels also carry a boxed warning about thyroid C-cell tumors, based on rodent studies. Most stomach side effects, like nausea, are worst in the first months and fade for most people.
How long have GLP-1 drugs been studied?
GLP-1 drugs for type 2 diabetes have been sold since 2005, when exenatide was approved, so there are about 20 years of real-world use in diabetes. For weight loss doses, the longest large trial is SELECT, where people on semaglutide 2.4 mg or placebo were followed for an average of about 3.3 years. Tirzepatide has 3-year data from SURMOUNT-1.
Do GLP-1 drugs cause cancer long term?
Not as far as human studies show so far. Semaglutide and tirzepatide caused thyroid C-cell tumors in rats and mice, so the labels carry a boxed warning, and people with a personal or family history of medullary thyroid cancer or MEN 2 should not use them. A 2024 BMJ study of over 145,000 GLP-1 users in Scandinavia found no clear rise in thyroid cancer. Some observational studies even link GLP-1 use to lower rates of obesity-related cancers, but they cannot prove cause.
What happens long term after stopping a GLP-1?
Most people regain weight. One year after stopping semaglutide in the STEP 1 extension, people had regained about two thirds of the weight they lost, and blood pressure and blood sugar gains also faded. This is the effect of the drug wearing off, not a lasting harm, but it matters for planning.
Do GLP-1 drugs cause muscle loss long term?
Some of the weight lost is lean mass. In a body scan substudy of STEP 1, roughly 40% of the weight lost on semaglutide was lean mass, which includes muscle, water and organs. Eating enough protein and doing strength training is the best way to keep more of your muscle.
Do GLP-1 drugs cause vision loss?
A rare eye condition called NAION has been linked to semaglutide in some studies. In 2025 the European Medicines Agency listed it as a very rare side effect, affecting up to 1 in 10,000 people. The US Wegovy label revised in June 2026 does not list it. Sudden vision loss in one eye needs same-day medical care.
Which GLP-1 has the least long term side effects?
There is no head-to-head study that answers this for long term use. Semaglutide and tirzepatide share the same label warnings. The best choice depends on your health history, other medicines and insurance, so it is a question for your prescriber.